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Abstract
Introduction
Hypertensive disorders of pregnancy (HDP) are a leading cause of global perinatal (fetal
and neonatal) and maternal morbidity and mortality. We sought to describe HDP and deter-
mine the magnitude and risk factors for adverse perinatal and maternal outcomes among
women with HDP in southwestern Uganda.
Methods
We prospectively enrolled pregnant women admitted for delivery and diagnosed with HDP
at a tertiary referral hospital in southwestern Uganda from January 2019 to November 2019,
excluding women with pre-existing hypertension. The participants were observed and
adverse perinatal and maternal outcomes were documented. We used multivariable logistic
regression models to determine independent risk factors associated with adverse perinatal
and maternal outcomes.
Results
A total of 103 pregnant women with a new-onset HDP were enrolled. Almost all women,
93.2% (n = 96) had either pre-eclampsia with severe features or eclampsia. The majority,
58% (n = 60) of the participants had an adverse perinatal outcome (36.9% admitted to the
neonatal intensive care unit (ICU), 20.3% stillbirths, and 1.1% neonatal deaths). Fewer par-
ticipants, 19.4% (n = 20) had an adverse maternal outcome HELLP syndrome (7.8%), ICU
admission (3%), and postpartum hemorrhage (3%). In adjusted analyses, gestational age of
< 34 weeks at delivery and birth weight <2.5kg were independent risk factors for adverse
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perinatal outcomes while referral from another health facility and eclampsia were indepen-
dent risk factors for adverse maternal outcomes.
Conclusion
Among women with HDP at our institution, majority had preeclampsia with severe symptoms
or eclampsia and an unacceptably high rate of adverse perinatal and maternal outcomes;
over a fifth of the mothers experiencing stillbirth. This calls for improved antenatal surveil-
lance of women with HDP and in particular improved neonatal and maternal critical care
expertise at delivering facilities. Earlier detection and referral, as well as improvement in initial
management at lower level health units and on arrival at the referral site is imperative.
Introduction
Hypertensive disorders of pregnancy (HDP) including gestational hypertension, preeclampsia,
and eclampsia complicate 2–8% of all pregnancies globally [1]. In developing countries where
the incidence of HDP is estimated to be seven times higher compared to developed countries,
these disorders are a leading cause of maternal and neonatal mortality and morbidity [2]. At
the Mbarara Regional Referral Hospital in Uganda, a tertiary care hospital caring for a largely
rural and agrarian population, HDP is the third leading cause of maternal death after puerperal
sepsis and obstetric hemorrhage [3]. Reducing and averting morbidity and mortality from
HDP requires early detection, treatment with antihypertensive therapy, seizure prophylaxis
and prompt delivery in severe cases [4–7].
To date, most studies examining maternal and perinatal outcomes in women with HDP
from sub-Saharan Africa have been limited to retrospective and cross-sectional data [7–17].
Additionally most studies from sub-Saharan Africa are from institutions based in large urban
and metropolitan areas, thus data is lacking on outcomes among women with HDP seeking
care in more rural and agrarian settings [9, 12, 15, 18]. Existing data suggest an increased risk
of maternal and perinatal adverse outcomes in women with HDP compared to women without
HDP [15, 17, 19, 20]. Several demographic (age, education, rural domicile), medical (pre-exist-
ing hypertension, multiparity, gestational age at delivery) and management (timing of drug
administration) characteristics have been identified as risk factors for adverse perinatal and
maternal outcomes among women with HDP [9–11, 14, 15, 21–23]. However, it is unknown if
similar rates of adverse outcomes and risk factors persist in a mostly rural population.
An improved understanding of the rate of adverse outcomes and characteristics associated
with these outcomes, will provide the basis for health system improvement and the develop-
ment of protocols to guide the identification of at-risk mothers and babies and implement
interventions to improve their birth outcomes.
We sought to describe HDP in a prospective cohort of women delivering in rural Uganda
and determine the magnitude and risk factors for adverse perinatal and maternal outcomes
among women with HDP at Mbarara Regional Referral Hospital.
Material and methods
Study design and setting
We conducted a prospective cohort study of women with hypertensive disorders of pregnancy
admitted for delivery at Mbarara Regional Referral Hospital (MRRH), in Southwestern
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Uganda from January 2019 to November 2019. MRRH is a government funded public hospital
that conducts approximately 9000 deliveries per year, with a caesarean delivery rate of 40%,
maternal mortality rate of 261 per 100,000 live births and perinatal mortality rate of 33 per
1000 live birth according to the 2019 hospital records.
Participants
Our study population included all pregnant women, including emancipated minors under the
age of 18 years, at� 20 weeks of gestation with new-onset hypertension in pregnancy diag-
nosed at admission. We defined hypertension as two blood pressure readings with either a sys-
tolic blood pressure� 140 or diastolic� 90 mmHg) measured 4 hours apart. Women
reporting a history of hypertension prior to pregnancy or prior to 20 weeks of gestation diag-
nosed by a health care provider, or taking an antihypertensive medication prior to pregnancy
were considered to have chronic hypertension and excluded from participation.
A prior study auditing vital sign assessment at MRRH found only 50% of women had blood
pressure checked as part of routine clinical care on admission [24]. Thus, to capture women
meeting the study eligibility criteria, all pregnant women presenting at the maternity ward of
MRRH for admission, had a screening blood pressure performed by research staff on admis-
sion. Women with an elevated blood pressure at admission had a subsequent check 4 hours
later. Women who were normotensive at admission and developed an elevated blood pressure
at a later time point during their labor course or postpartum course were not included in the
study. Women who met the inclusion criteria and consented to the study were enrolled at
admission and followed up to 12 weeks postpartum. This study was part of a prospective
cohort study to examine the magnitude of persistent hypertension at 12 weeks postpartum
after HDP. Mothers were interviewed at admission, discharge, 6 weeks postpartum and 12
weeks postpartum by trained study staff.
Variables and data sources
We classified enrolled women a priori as those with gestational hypertension, pre-eclampsia,
pre-eclampsia with severe features and eclampsia at admission. Gestational hypertension was
defined as new-onset hypertension without proteinuria. Pre-eclampsia was defined as new
onset hypertension with proteinuria. The study team assessed for proteinuria (defined as� 2
+ protein) in all enrolled women at admission using a dipstick of a mid-stream urine sample.
Severe features of pre-eclampsia included any of the following: blood pressure of�160 mmHg
systolic or�110 mmHg diastolic,� 3+ protein by dipstick, persistent epigastric pain, persis-
tent headache, visual changes or elevated serum creatinine [4, 25]. A blood sample was drawn
at recruitment for study purposes and analysed for renal (serum creatinine and urea) function.
Liver function tests and complete blood count were abstracted from the chart if performed for
clinical purposes. Women with grand mal seizures unrelated with other cerebral conditions
who had signs and symptoms of preeclampsia were defined as having eclampsia [26].
The primary outcome measures were adverse perinatal and maternal outcomes occurring
during the participant’s hospital stay or within seven days of delivery, whichever came first
and these were determined a priori. An adverse perinatal outcome was defined as a composite
of one or more of the following: antepartum stillbirth (fetal death prior to the onset of labor),
intrapartum stillbirth (fetal death occurring after the onset of labor and prior to delivery),
admission to the neonatal intensive care unit (NICU) or neonatal death by discharge or within
seven days, whichever came first. Adverse maternal outcome was defined as a composite of
one or more of the following: hysterectomy, laparotomy (women delivered vaginally who later
require abdominal exploration, or a post cesarean section mother who required re-operation
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for abdominal exploration), primary postpartum hemorrhage (estimated blood loss
of> 500mls following vaginal delivery or >1000mls following cesarean delivery within 24
hours after delivery as documented in the participant’s medical forms), admission to Intensive
Care Unit (ICU), stroke, HELLP (Hemolysis Elevated Liver enzymes and Low Platelets) syn-
drome and blood transfusion. All adverse outcomes were obtained by chart abstraction from
the participant medical forms.
Other covariates of interest included socio-demographic characteristics, past medical his-
tory, obstetric history and obstetric care factors. This information was obtained using an inter-
viewer administered questionnaire during participant enrollment and a second questionnaire
administered at discharge. Socio-demographic data included maternal age, marital status, level
of education and referral status (i.e. women referred in to MRRH from another health center).
Medical history included HIV status (HIV positive or negative result done within 3 months),
history of chronic kidney disease and history of diabetes mellitus. Pre-pregnancy body mass
index (BMI) was not available, however, we measured weight and height at enrollment to the
study, and calculated the BMI (weight in kilograms divided by height in meters squared) from
this measurement. We then classified women as underweight (<18.5kg/m2), normal weight
(18.5–24.9kg/m2), overweight (25-29kg/m2) and obese�30kg/m2) at data analysis. Obstetric
data collected included parity, mode of delivery, gestational age at delivery (determined pri-
marily using the last normal menstrual period (LNMP) or first trimester obstetric ultrasound
scan if available and LNMP was unknown), history of hypertension in previous pregnancy and
eclampsia (grand mal convulsions). Obstetric care factors included the time to delivery (calcu-
lated as admission date/time to date/time of delivery), administration of antenatal corticoste-
roids (for women at 28 to 33 weeks of gestation according to the MRRH protocols),
magnesium sulfate and antihypertensive treatment, captured from chart abstraction of the par-
ticipant medical forms. Study data were collected and managed using REDCap electronic data
capture tools hosted at MUST Department of OB/GYN. REDCap (Research Electronic Data
Capture) is a secure, web-based software platform designed to support data capture for
research studies [27, 28].
Sample size and power
The sample size was based on the primary cohort study examining persistent hypertension.
For this sub-study, sample size and power were therefore not determined a priori.
Data analysis
Maternal socio-demographic, medical and obstetric characteristics were presented in fre-
quency tables stratified by type of hypertensive disorder. Univariate analysis for risk factors for
adverse maternal and perinatal outcomes was performed using crude risk ratios. Factors with
a p value of� 0.2 at univariate analysis were considered for inclusion in the adjusted analysis.
Multiple logistic regression models were used to determine the independent risk factors with
their corresponding 95% confidence intervals [29]. A p-value less than 0.05 was considered
statistically significant. Data analysis was performed with Stata version 15. (Statacorp, College
Station, TX, USA).
Ethical consideration
The study procedures were approved by the Mbarara University Research Ethics Committee
(07/09-18), Uganda National Council for Science and Technology (HS 2570) and Partners
Healthcare Institutional Review Board (2019P001446). Participants provided written informed
consent.
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Results
There were 9,096 deliveries at MRRH during the study period (January-November 2019). Of
these, 155 women with hypertension in pregnancy upon admission to the maternity ward
were screened for eligibility. Of these, 6 were excluded due to pre-existing hypertension before
pregnancy, and 38 declined consent. Thus, a total 103 women with new-onset hypertension
during pregnancy were enrolled. Of these 103 women, 4.9% (n = 5) had gestational hyperten-
sion, 1.9% (n = 2) had preeclampsia with mild features, 71.8% (n = 74) had pre-eclampsia with
severe features and 21.4% (n = 22) had eclampsia.
Participant characteristics are shown in Table 1. The mean age was 27 years (SD±6). Most
participants were multigravida 65% (n = 67), referred from other health facilities 63.1%
(n = 65) and delivered preterm at gestational age<37 weeks 61.3% (n = 57). Over a quarter of
participants were obese (27.6%, n = 27). Most women, 61.8% (n = 63) were delivered by cesar-
ean section and 42.2% (n = 43) within 24 hours of admission. The majority of babies had either
a low birth weight 37.1% (n = 36) or a very low birth weight 20.6% (n = 20). Almost all the par-
ticipants 96.1% (n = 99) received anti-hypertensive medication and 92.6% (n = 87) received
magnesium sulfate. Less than half, 44.7% (n = 42) received a complete dose of magnesium sul-
fate, only 31% (n = 9) of the women at gestational age< 34 weeks received antenatal cortico-
steroids. Data on age 1% (n = 1), body mass index 4.8% (n = 5), gestational age at delivery
9.7% (n = 10), eclampsia 3.9% (n = 4), mode of delivery 1% (n = 1), time to delivery 1%
(n = 1), and magnesium sulfate administration 8.7% (n = 9) were missing.
Adverse perinatal and maternal outcomes are reported in Table 2. Overall, 58% (n = 60)
participants experienced one or more adverse perinatal outcome and 19.4% (n = 20) one or
more adverse maternal outcome. Adverse perinatal outcomes included admission to the
NICU 36.9% (n = 38), stillbirth 20.3% (n = 21) and neonatal death before discharge 1.1%
(n = 1). Of the 21 stillbirths, 76.2% (n = 16) were antepartum stillbirths and 23.8% (n = 5) were
intrapartum stillbirths. Adverse maternal outcome included HELLP syndrome 7.8% (n = 8),
blood transfusion 2.9% (n = 3), ICU admission 2.9% (n = 3) and postpartum hemorrhage 2.9%
(n = 3).
In an adjusted analysis controlling for history of HDP in prior pregnancy, administration
of magnesium sulfate and gravidity, the independent risk factors for adverse perinatal out-
comes were gestational age at delivery <34 (aRR 1.6; 95% CI, 1.2–2.3; p<0.01) and birth
weight <2.5kg (aRR 1.4; 95% CI, 1.1–2.1; p = 0.02) as shown in Table 3.
In an adjusted analysis controlling for level of education, mode of delivery and magnesium
sulfate administration, the independent risk factors for adverse maternal outcomes were refer-
ral from another facility (aRR 3.9; 95% CI, 1.1–13.8; p< 0.01) and eclampsia (aRR 3.7; 95% CI,
1.6–8.4; p = 0.01) as shown in Table 4.
Discussion
In this prospective cohort study of women with hypertensive disorders of pregnancy we found
a high rate of severe HDP, and high rates of both perinatal and maternal adverse outcomes,
with almost two-third of babies having an adverse perinatal outcome and a fifth of women
experiencing an adverse maternal outcome. Preterm delivery and low birth weight were inde-
pendent significant risk factors for adverse perinatal outcomes as expected. Referral from
another facility and eclampsia were independent and significant risk factors for adverse mater-
nal outcomes.
The majority of women in this cohort had either pre-eclampsia with severe disease or
eclampsia; together accounting for 93.2% of the cohort. The high rates of adverse perinatal and
maternal outcomes reflects this severity and are comparable to findings in other SSA settings.
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Reported stillbirth rates among women with HDP in SSA range from 6.8%-22.6%, NICU
admissions from 24.7% - 28.8% and neonatal deaths from 3% - 14.1% [7, 9, 11–13, 15, 16, 30].
In cohorts of women with HDP in SSA, HELLP syndrome is reported in 0.8%-13% of women,
PPH in 5.9%-7% and ICU admission in 5.7%-29.3% [13–15, 17, 18, 26, 31]. Our findings on
the rate of NICU admission and neonatal deaths fall in the lower end of the range of those
reported these studies. However, we found a rate of stillbirth that falls on the high end of the
reported range and includes a high proportion (over 70%) of antepartum stillbirths. HELLP
syndrome was the commonest adverse maternal outcome and may be under reported as not
all patients in this cohort had lab evaluation beyond those done for study purposes. This shows
the need to have laboratory services at health facilities able to do full blood count and liver
Table 1. Participant characteristics.
Participant Characteristics n = 103 n (%)
Age n = 102 <35 85 (83.3)
�35 17 (16.7)
Marital Status Not Married 7 (6.8)
Married 96 (93.2)
Level of Education Primary and below 50 (48.5)
Secondary and above 53 (51.5)
Referral from another facility Not Referred 38 (36.9)
Referred 65 (63.1)
Gravidity Primgravida 36 (35)
Multigravida 67 (65)
History of HDP in a prior pregnancy Yes 13(12.6)
No 90 (87.4)
Body Mass Index n = 98 Underweight 1 (1)
Normal 30 (30.6)
Over weight 40 (40.8)
Obese 27 (27.6)
Gestational Age at delivery n = 93 <28 6 (6.4)
28–33 29 (31.2)
34–36 22 (23.7)
�37 36 (38.7)
HIV status Positive 7 (6.8)
Negative 96 (93.2)
Eclampsia n = 99 No 77 (77.8)
Yes 22 (22.2)
Mode of Delivery n = 102 Vaginal delivery 39 (38.2)
Cesarean section 63 (61.8)
Time to delivery n = 102 Within 24 hours 43 (42.2)
> 24 hours 59 (57.8)
Steroid administration Received 9 (31)
Not Received 20 (69)
Anti-Hypertensive medicine Received 99 (96.1)
Not Received 4 (3.9)
Magnesium Sulfate administration n = 94 Complete dose 42 (44.7)
Loading dose only 19 (20.2)
Incomplete dose 26 (27.7)
Not Received 7 (7.4)
https://doi.org/10.1371/journal.pone.0241207.t001
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function tests. This will help in early identification of these women with evidence of organ dys-
function in order to institute the appropriate management.
These findings, along with the risk factors identified including gestational age at delivery,
low birth weight, eclampsia and referral from another facility have several implications. This is
because these factors suggest a possible delay in early detection of HDP, prompt treatment
with antihypertensive therapy, timely administration of seizure prophylaxis and prompt deliv-
ery which measures have been shown to reduce and avert morbidity and mortality. Preterm
delivery in many cases is due to the need for delivery to enable definitive management for
HDP. Low birth weight as an independent risk factor likely represents undiagnosed intrauter-
ine fetal growth restriction. However, the need for early delivery, and evidence for fetal growth
restriction emphasize the severity of disease in this cohort and point to the need for strength-
ening antenatal fetal surveillance and the monitoring of mothers with hypertensive disorders
of pregnancy, as well as the need for prevention strategies such as the use of aspirin prophylaxis
in appropriate candidates [32]. Secondly, once delivered it is clear that babies born to women
with HDP are in need of prompt and specialized care. Our findings highlight the need for
functional NICUs, trained NICU nurses and neonatologists and protocols for neonatal resus-
citation to improve the outcomes of the babies delivered prematurely and with low birth
weight.
Furthermore, women with eclampsia and those who were referred from another facility
had a significantly increased risk for adverse maternal outcomes. Mothers with eclampsia may
have neurological dysfunction, metabolic coma, stroke, uncontrollable fits and eclamptic
encephalopathy [26]. The severity of disease on admission with a high rate of severe features
and high rate of eclampsia emphasizes gaps in early identification and treatment. Delays in
diagnosis and management due to referral from one facility to another are well described in
the obstetric literature [33, 34]. Transfer from one facility to another introduces several time
points where gaps in care may occur: at the facility initiating the referral, en route, and upon
arrival at the receiving facility. At each stage, inadequate numbers of trained staff, equipment,
medications and systems to identify at-risk women compound the potential for women to
develop complications.
Although we demonstrate a high rate of anti-hypertensive use in this population, we noted
less than half of the women received appropriate dosing of magnesium sulfate, and even fewer
Table 2. Frequency and distribution of adverse perinatal and maternal outcomes.
Adverse perinatal outcome n (%)
Intrapartum stillbirth 5 (4.8)
Antepartum stillbirth 16 (15.5)
Admission to Neonatal Intensive Care Unit 38 (36.9)
Death of infant before discharge 1 (1.1)
One or more adverse perinatal outcome 60 (58)
Adverse maternal outcomes n (%)
Hysterectomy 1 (1.0)
Laparotomy 1 (1.0)
Blood transfusion 3 (2.9)
Admission to Intensive Care Unit 3 (2.9)
Postpartum hemorrhage 3 (2.9)
Stroke 1 (1.0)
HELLP syndrome 8 (7.8)
One or more adverse maternal outcome 20 (19.4)
https://doi.org/10.1371/journal.pone.0241207.t002
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antenatal steroids for fetal lung maturity with a trend towards the most severe cases, i.e. those
receiving treatments had a non-significant increase in the risk of adverse outcomes. These
findings highlight a need to develop training protocols and ensure drug availability that can
extend prophylactic measures to more women to prevent adverse outcomes. Given the severity
noted at admission to this tertiary care center it is clear that such management needs to occur
earlier in the referral chain. Thus, a focus on ensuring training protocols and system reforms
occur at lower level health care will be essential to improve outcomes among women with
HDP.
Our study has some limitations. The study was conducted in a single regional referral hos-
pital in southwestern Uganda and the findings may not be generalizable to all the other
regional referral hospitals in Uganda, or other levels of facilities. As a referral hospital, our
cohort may be skewed towards women with more advanced or severe disease. Additionally, we
Table 3. Risk factors for adverse perinatal outcomes.
Characteristic Adverse fetal outcome n = 60 Crude Risk Ratio p value Adjusted Risk Ratio p value
Age category <35 48 (80.0) ref
�35 12 (20.0) 1.3 (0.9,1.8) 0.28 - -
Marital Status Single 5 (8.3) ref
Married 55 (91.7) 0.8 (0.5,1.3) 0.46 - -
Level of Education Primary and below 30 (50.0) ref
Secondary and above 30 (50.0) 0.9 (0.7,1.3) 0.73 - -
Referred from another health center Not Referred 21 (35.0) ref
Referred 39 (65.0) 1.1 (0.8,1.5) 0.64 - -
HIV Status Negative 56 (93.3) ref
Positive 4 (6.7) 1.0 (0.5,1.9) 0.95 - -
Gravidity Primgravida 14 (23.3) ref
Multigravida 46 (76.7) 1.8(1.1,2.7) <0.01 1.3 (0.9,1.8) 0.09
History of HDP in prior pregnancy No 49 (81.7) ref
Yes 11 (18.3) 1.6 (1.2,2.1) 0.04 1.2(0.7,2.0) 0.40
Mode of Delivery Vaginal delivery 26 (43.3) ref
C-section 34 (56.7) 0.8 (0.6,1.1) 0.21 -
Gestational Age at Delivery �34 22 (40.0) ref
< 34 33 (60.0) 2.5 (1.8,3.5) <0.01 1.6(1.2,2.3) <0.01
BMI at admission Not Obese (<30) 40 (71.4) ref
Obese (�30) 16 (28.6) 1.1 (0.7,1.5) 0.79 - -
Eclampsia No 43 (74.1) ref
Yes 15 (25.9) 1.2(0.9,1.7) 0.33 - -
Birth weight � 2.5kg 13 (23.2) ref
<2.5kg 43 (76.8) 2.4 (1.5,3.9) <0.01 1.4(1.1,2.1) 0.02
Time to Delivery Within 24 hours 22 (36.7) ref
> 24 hours 38 (63.3) 1.2 (0.9,1.8) 0.21 - -
Anti- Hypertensive Given 59 ref
Not Given 1 0.4 (0.1,2.3) 0.17 - -
Steroid administration Given 9 ref
Not Given 18 0.9 (0.8,1.0) 0.32 - -
Magnesium Sulfate administration Given 32 ref
Not Given 23 0.6 (0.4,0.8) 0.01 0.8 (0.6,1.0) 0.07
Adjusted for history of HDP in prior pregnancy, administration of magnesium sulfate and gravidity.
https://doi.org/10.1371/journal.pone.0241207.t003
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were only able to obtain adverse outcomes that occurred while in the hospital, therefore we
would not have captured any additional adverse outcomes that occurred after discharge and in
the community or another facility. Our estimates may thus underestimate the true burden in
this cohort of women. In our study HELLP syndrome was reported documentation available
in the participants’ medical records. Thus liver function tests and platelet counts were only
available if done for clinical purposes. As these lab tests are not routinely available, this might
have led to under estimation of participants with HELLP syndrome for those who did not do
the tests. Lastly, we did not enroll women who were normotensive at admission and developed
hypertension during the course of their labour and in the postpartum period, so we likely
underestimated the burden of hypertension at this facility.
Conclusion
Most women in this cohort had an adverse perinatal outcome, with over a fifth experiencing a
stillbirth. Given stagnation in reduction of global stillbirth and neonatal mortality rates, this
study identifies women with preeclampsia as target group. Similarly, given high rates of
Table 4. Risk factors for adverse maternal outcomes.
Characteristic Adverse maternal outcomes Crude Risk Ratio p value Adjusted Risk Ratio p value
Yes = 20
Age category <35 18 (90.0) ref
�35 2 (10.0) 0.6 (0.1,2.2) 0.37 - -
Marital Status Single 1 (5.0) ref
Married 19 (95.0) 1.4 (0.2,8.9) 0.72 - -
Level of Education Primary and below 7 (35.0) ref
Secondary and above 13 (65.0) 1.8 (0.8,4.0) 0.18 1.7 (0.8,3.6) 0.14
Referred from another health center Not Referred 4 (20.0) ref
Referred 16 (80.0) 2.3 (0.8,6.5) 0.08 3.9 (1.1,13.8) <0.01
HIV Status Negative 19 (95.0) ref
Positive 1 (5.0) 0.7 (0.1,4.6) 0.72 - -
Gravidity Primgravida 8 (40.0) ref
Multigravida 12 (60.0) 0.8 (0.4,1.8) 0.60 - -
History of HDP in prior Pregnancy No 17 (85.0) ref
Yes 3 (15.0) 1.2 (0.4, 3.6) 0.72 - -
Mode of Delivery Vaginal delivery 5 (25.0) ref
C-section 15 (75.0) 1.8 (0.7,4.7) 0.17 1.8 (0.7,4.8) 0.26
Body Mass Index Not Obese (<30) 14 (77.8) ref
Obese (�30) 4 (22.2) 0.8 (0.3,2.1) 0.58 -
Eclampsia No 8 (44.4) ref
Yes 10 (55.6 4.4 (1.9,9.7) <0.01 3.7 (1.6,8.4) 0.01
Time to Delivery Within 24 hours 11 (57.9) ref
> 24 hours 8 (42.1) 0.5 (0.2,1.2) 0.11
Anti- Hypertensive Given 20
Not Given 0 0 0.32
Steroid administration Given 3
Not Given 2 0.3 (0.1,1.4) 0.12
Magnesium Sulfate administration Given 14
Not Given 5 0.3 (0.1,0.7) 0.01 0.4 (0.2,1.1) 0.05
Adjusted for level of education, mode of delivery and magnesium sulfate administration.
https://doi.org/10.1371/journal.pone.0241207.t004
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specialized neonatal care needed and risk factors of prematurity and low birth weight, strate-
gies are needed to identify women at risk and triage delivery to facilities with neonatal exper-
tise. There is need to have well equipped and functional NICU, NICU nurses and
neonatologists. Quality improvement strategies also need to be put in place to target the refer-
ral pathways and immediate critical care and stabilization of women with hypertensive disor-
ders of pregnancy to prevent eclampsia and improve the outcomes of these mothers.
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